Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) — Stella
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
(13 sites) France
HCL - Groupement Hospitalier Est Hôpital Femme-Mère-Enfant, Bron Chu Estaing, Clermont-Ferrand Chu Dijon Bourgogne, Dijon CHU Dijon Bourgogne - CIC-P, Dijon AP-HP Hôpital Necker-Enfants Malades - CIC, Paris AP-HP Hôpital Necker-Enfants Malades, Paris
Key details Sponsor
Centre Hospitalier Universitaire Dijon
Collaborators
Novartis Pharmaceuticals
Enrollment target
~20 participants
Primary completion
March 2027
Last updated February 2026